These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8934730)

  • 21. Adjuvant chemotherapy of stage III colon cancer.
    Benson AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S74-7. PubMed ID: 16399437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
    de Gramont A; Louvet C; Krulik M
    J Infus Chemother; 1996; 6(3):133-6. PubMed ID: 9229324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
    Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
    Nakata B; Sowa M; Tsuji A; Kamano T; Sasaki K; Fukunaga Y; Takahashi M; Tsujitani S; Mikami Y; Mitachi Y; Nishimura S; Araki H; Yamamitsu S; Hirakawa K; Tominaga S; Shirasaka T; Inokuchi K
    J Exp Clin Cancer Res; 2007 Mar; 26(1):51-60. PubMed ID: 17550132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons.
    Anderson N; Lokich J
    Cancer; 1992 Aug; 70(4 Suppl):998-1002. PubMed ID: 1638471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy in metastatic colorectal cancer.
    Hansen RM
    Arch Intern Med; 1990 Nov; 150(11):2265-9. PubMed ID: 2241436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy for colorectal cancer: an overview.
    Mayer RJ
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):62-6. PubMed ID: 1948131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
    Wilke H; Stahl M; Köster W; Vanhöfer U
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():3-8. PubMed ID: 10941246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infusional 5-FU: historical evolution, rationale, and clinical experience.
    Lokich J
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):19-22. PubMed ID: 9830620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer chemotherapy and infusional scheduling.
    Anderson N; Lokich JJ
    Oncology (Williston Park); 1994 May; 8(5):99-111; discussion 111, 115-6. PubMed ID: 8025010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current approaches to metastatic colorectal cancer.
    Kemeny N
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):67-75. PubMed ID: 8091243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pros and cons of infusional 5-FU as adjuvant therapy for colon cancer.
    Macdonald JS
    Oncology (Williston Park); 1990 Jan; 4(1):67. PubMed ID: 2144180
    [No Abstract]   [Full Text] [Related]  

  • 35. Schedule dependency of 5-fluorouracil.
    Leichman CG
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):26-32. PubMed ID: 10442355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-FU/leucovorin: biochemical modulation that works?
    Arbuck SG
    Oncology (Williston Park); 1987 Apr; 1(2):61-74. PubMed ID: 3079477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.
    Schmoll HJ
    Eur J Cancer; 1996; 32A Suppl 5():S18-22. PubMed ID: 8958038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on biochemical modulation of chemotherapeutic agents.
    Kobayashi K; Schilsky RL
    Oncology (Williston Park); 1993 May; 7(5):99-106, 109; discussion 110-4, 117. PubMed ID: 8512789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the treatment of advanced colorectal cancer.
    Kemeny N; Lokich JJ; Anderson N; Ahlgren JD
    Cancer; 1993 Jan; 71(1):9-18. PubMed ID: 8416731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of leucovorin dosing and administration schedule.
    Jolivet J
    Eur J Cancer; 1995; 31A(7-8):1311-5. PubMed ID: 7577042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.